

(i) an effective amount of at least one supplement selected from the group consisting of a growth factor, an antibody, a polynucleotide or oligonucleotide, a cytotoxin or cell proliferation inhibiting compound, an osteogenic or cartilage inducing compound, an antimicrobial composition, an analgesic, an anesthetic, an anticoagulant, an antiinflammatory compound, a cytokine, a chemotherapeutic drug, a hormone, an interferon, a lipid, a polysaccharide, a protease inhibitor, a proteoglycan, a steroid, a vasoconstrictor, a vasodilator, a vitamin, and a nutritional mineral, and

(ii) a biocompatible tissue sealant composition comprising fibrinogen or a derivative or metabolite thereof in an amount which [is capable of forming] forms a fibrin matrix [in the presence of thrombin, Factor XIII and Ca⁺⁺].

13. (Amended) The delivery system of claim 12, wherein [the supplemented tissue sealant composition] said delivery system is [delivered] placed in close proximity to tissue of a patient, thereby permitting the localized release of said [antibody] supplement to the tissue of said patient.

14. (Amended) The delivery system of [claims 12 or] claim 13, wherein said localized release of [the antibody] said supplement is sustained release.

15. (Amended) The delivery system of [claims] claim 14, wherein [the antibody] said supplement is of sufficiently low solubility to permit localized, sustained-release of [antibody] said supplement.

BEST AVAILABLE COPY

16. (Amended) The delivery system of [claims] claim 14, wherein the mass of [antibody] supplement exceeds an amount which is soluble in [the volume of] the fibrin matrix, thereby permitting localized, sustained-release of [antibody] said supplement.

17. (Amended) The delivery system of claim [16] 14, wherein said [antibody] supplement is introduced into said [matrix] biocompatible tissue sealant composition as an emulsion.

18. (Amended) The delivery system of [claims] claim 14, wherein said [antibody] supplement interacts with said fibrin matrix, thereby permitting localized, sustained-release of said [antibody] supplement.

19. (Amended) The delivery system of claim 14, wherein said [antibody] supplement is in solid form.

20. (Amended) The delivery system of claim 19, wherein said [antibody] supplement is introduced into said [matrix] biocompatible tissue sealant composition in solution in a carrier, said carrier having a higher rate of dissolution or diffusion in said fibrin matrix than said composition contained therein, so that [the composition] said supplement is deposited within [the] said fibrin matrix as a solid precipitate.

Please add the following new claims 24-33:

BEST AVAILABLE COPY

~~24. The delivery system of claim 13, wherein said supplement is a cytotoxin or cell proliferation inhibiting compound and said tissue is a neoplastic or hyperproliferative lesion of a patient and tissue adjacent thereto.~~

32
25. The delivery system of claim 12, wherein said supplement is a growth factor selected from the group consisting of: fibroblast growth factors; platelet-derived growth factors; insulin-binding growth factors; epidermal growth factors; transforming growth factors; cartilage-inducing factors; osteoid-inducing factors; osteogenin and other bone growth factors; bone morphogenetic growth factors; collagen growth factors; heparin-binding growth factors; cytokines; interferons; hormones and biologically active derivatives of said growth factors.

26. The delivery system of claim 12, wherein said supplement is an osteogenic or cartilage inducing compound selected from the group consisting of: cartilage-inducing factors; osteoid-inducing factors; osteogenin and other bone growth factors which modulate the proliferation, migration and/or attraction of progenitor bone cells; bone morphogenetic growth factors; demineralized bone matrix; and biologically active derivatives of said compounds.

27. The delivery system of claim 12, wherein said supplement is an antibody.

28. The delivery system of claim 12, wherein said supplement is a polynucleotide or an oligonucleotide.

33
C3
BEST AVAILABLE COPY

29. The delivery system of claim 12, wherein said supplement is an antimicrobial compound.

30. The delivery system of claim 12, wherein said biocompatible tissue sealant composition further comprises thrombin or other activator of fibrin formation.

31. The delivery system of claim 12, wherein said biocompatible tissue sealant composition further comprises Factor XIII.

32. The delivery system of claim 12, wherein said biocompatible tissue sealant composition further comprises Ca^{++} .

33. The delivery system of claim 14, wherein said supplement is introduced into said biocompatible tissue sealant composition in solution in a carrier, -

Remarks

In view of the foregoing amendments and the following remarks, Applicants respectfully request reconsideration and withdrawal of all outstanding objections and rejections and early allowance of the above-identified application.

Upon entry of the foregoing amendment, claims 12-33 are pending in the application, with claim 12 being the sole independent claim. New claims 24-33 are sought to be added. These changes are believed to introduce no new matter, and their entry is respectfully requested.

BEST AVAILABLE COPY